Teladoc Health Inc. (NYSE: TDOC) is a telehealth service that can help patients diagnose and treat non-emergency conditions like the flu, allergies, and upper respiratory infections.
In 2020, the company’s medical consultation business saw demand surge, and with it, the firm’s share value climbed by 138%.
But with the release of COVID-19 vaccines and the return to more normal economic activity, TDOC shares have pulled back by 21%.
Even with people returning to in-person physicians, all isn’t lost for the company.
In fact, it’ll likely be fine, as it was never truly realistic to expect the rapid growth rate from last year to continue indefinitely.
Currently, the firm forecasts revenue will grow by 82% in 2021.
And while that’s below last year’s 98% growth, the telehealth industry is expected to continue to grow, and even blend with traditional visitations to clinics.
Even if that’s on the more long-term side of things, the rising number of delta-variant infections in the U.S. – and around the world – has many health experts forecasting a return of some restrictions in the fall and winter season, potentially providing a boost to TDOC services.
New Breakthrough Can… “Cut & Paste” Disease From Your Body
Sponsored
Big Pharma loves to buy small biotech’s right after the market drops.
When the market dropped 19% in the fourth quarter of 2018, Ex-Wall Street CEO Dylan Jovine picked 3 biotech stocks ripe for a takeover.
On October 1st, 2018, he recommended Tesaro… 63 days later it was taken over for an easy 91% profit…
On October 19, 2018 he recommended Pacific Biosciences… 4 days later it was taken over for a quick 72% gain…
On January 4, 2019 he recommended Loxo Oncology… 3 days later it was taken over for a fast 71% gain…
Well guess what? The Coronavirus market drop has given Big Pharma its first takeover target of 2021.
In this special letter, you’ll learn why Dylan thinks now is the best time to make money with this tiny stock.
You’ll discover:
- Why Big Pharma firms Allergan, Celgene and others have invested over $1 billion into this tiny biotech.
- Why President Trump thinks this biotech’s breakthrough is a matter of national security.
- How a takeover could make you $41,250 in profits any day now.
That’s because in this letter, we’ll show you how get into this company right now – before it’s too late!
You don’t want to miss this.
